IOL-VIP system: new hope for low vision patients

Article

Besides external magnifying glasses, certain intraocular lenses and devices have been proposed as feasible visual aids for AMD patients.

Key Points

Hereditary or acquired macular degeneration causes severe central vision loss and, in spite of several new therapeutic procedures, reduces the capability of patients to perform day-to-day activities, such as reading, writing, and precise handling. Importantly, it can lead to legal blindness.

Once central vision has been lost, optical devices that increase retinal image size by angular magnification offer the only chance of improving visual function. Besides external magnifying lenses, certain intraocular lenses (IOL) and devices have been proposed as feasible visual aids in these patients.

The first is the Hanita implant, which has a central hyper-minus lens, associated with a spectacle hyperpositive lens. The second is the Implantable Miniature Telescope (IMT); a quartz glass telescope prosthesis, which is implanted monocularly to give one eye improved central vision, while the other eye is left alone to continue to provide peripheral vision for orientation and mobility. Both devices improve retinal image size, but significantly reduce peripheral visual field, thus hampering everyday activities. A third option is the IOL-VIP (Intraocular Lens for Visually Impaired People) system, which consists of both a surgical and a rehabilitation approach designed ultimately to improve vision capabilities in maculopathy patients.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.